Friday, 16 October 2026European Markets

HOSTELWORLD GROUP Stock Over 16% Up In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of HOSTELWORLD GROUP (ISEQ All Share: HSW.IR) rose by a staggering 16.67% in 5 sessions from €1.32 to €1.54 at 14:22 EST on Friday, after three successive sessions in a row of losses. ISEQ All Share is dropping 0.07% to €8,893.03, following the last session's downward trend.

HOSTELWORLD GROUP's last close was €1.38, 20.23% under its 52-week high of €1.73.

About HOSTELWORLD GROUP

Hostelworld Group plc operates an online booking platform worldwide. The company offers software and data processing services that facilitate hostel, B&B, hotel, and other accommodation bookings. The company also provides business information consulting and marketing planning services; and marketing, and research and development services. In addition, it is engaged in technology trading business. Hostelworld Group plc was founded in 1999 and is based in Dublin, Ireland.

Earnings Per Share

As for profitability, HOSTELWORLD GROUP has a trailing twelve months EPS of €-0.15.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -28.93%.

Volume

Today's last reported volume for HOSTELWORLD GROUP is 8381 which is 1224.01% above its average volume of 633.

Yearly Top and Bottom Value

HOSTELWORLD GROUP's stock is valued at €1.54 at 14:22 EST, way under its 52-week high of €1.73 and way higher than its 52-week low of €0.85.

Moving Average

HOSTELWORLD GROUP's value is above its 50-day moving average of €1.49 and way higher than its 200-day moving average of €1.26.

More news about HOSTELWORLD GROUP (HSW.IR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com